News
ACTU
1.680
-14.29%
-0.280
Weekly Report: what happened at ACTU last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at ACTU last week (0608-0612)?
Weekly Report · 06/15 09:26
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained
TipRanks · 06/10 10:25
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/09 21:06
Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma
Benzinga · 06/09 11:48
ACTUATE THERAPEUTICS’ ELRAGLUSIB SELECTED FOR EVALUATION IN BEACON2 TRIAL FOR HIGH-RISK PEDIATRIC NEUROBLASTOMA
Reuters · 06/09 11:45
Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma
PUBT · 06/09 11:45
Weekly Report: what happened at ACTU last week (0601-0605)?
Weekly Report · 06/08 09:25
Actuate Therapeutics posts ASCO presentation on elraglusib plus chemotherapy in metastatic pancreatic cancer
PUBT · 06/02 13:41
Actuate Therapeutics posts ASCO Phase II mPDAC presentation on FOLFIRINOX with elraglusib, losartan
PUBT · 06/02 13:41
Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO
Benzinga · 06/01 11:07
Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer
PUBT · 06/01 11:05
ACTUATE THERAPEUTICS ANNOUNCES ASCO POSTER PRESENTATIONS DEMONSTRATING COMPELLING CLINICAL AND BIOMARKER DATA FOR ELRAGLUSIB IN FIRST-LINE METASTATIC PANCREATIC CANCER
Reuters · 06/01 11:00
Weekly Report: what happened at ACTU last week (0525-0529)?
Weekly Report · 06/01 09:26
Weekly Report: what happened at ACTU last week (0518-0522)?
Weekly Report · 05/25 09:27
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor
TipRanks · 05/22 22:24
Actuate Therapeutics shareholders elected two directors at annual meeting
PUBT · 05/22 20:44
Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital
TipRanks · 05/18 17:55
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)
TipRanks · 05/18 10:20
Weekly Report: what happened at ACTU last week (0511-0515)?
Weekly Report · 05/18 09:27
More
Webull provides a variety of real-time ACTU stock news. You can receive the latest news about Actuate Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.